A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• advanced measurable Non-Small Cell Lung Cancer (NSCLC);

• progressed after 1-2 prior chemotherapy;

• Eastern Cooperative Oncology Group (ECOG) 0-2;

• tissue available for future KRAS/ EGFR testing

Exclusion Criteria:

• prior Epidermal Growth Factor Receptor (EGFR) targeted therapy;

• active or untreated Central Nervous System (CNS) metastases;